Renal Associates LLC is proud to announce that is now enrolling patients to clinical trials at our Bradley Park office. Participation in a clinical trial will enable you to access promising new therapies before they become widely available.

As of February 2017, we are actively enrolling participants to the following trials:

1. The ROXA trial:  to determine the safety and efficacy of roxadustat in the treatment of anemia of CKD; compares roxadustat vs. placebo
2. The CREDENCE trial:  to determine the safety and efficacy of canagliflozin in the prevention of progression of CKD in patients with type 2 diabetes; compares canagliflozin vs. placebo
3. The ZOLL trial:  to prevent first occurrence of cardiovascular events in patients recently starting hemodialysis using a wearable cardioverter defibrillator
4. The AKEBIA trial:  to determine the safety and efficacy of vadadustat in the treatment of anemia of CKD comparing vadadustat vs darbepoetin alfa in subjects on dialysis or non-dialysis
5. The ASCEND-ND trial:  to determine the safety and efficacy of daprodustat in the treatment of anemia of CKD in patients that are not on dialysis; compares daprodustat vs. dabepoetin alfa.
6. The ASCEND-D: to determine the safety and efficacy of daprodustat in the treatment of anemia of CKD on dialysis; compares daprodustat vs. dabepoetin alfa.
7. The Phase 2 DUET study:  the use of sparsertan in focal segmental glomerulosclerosis (FSGS) to determine the reduction in proteinuria